<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01317992</url>
  </required_header>
  <id_info>
    <org_study_id>U1111-1119-9613</org_study_id>
    <secondary_id>IBU-002</secondary_id>
    <nct_id>NCT01317992</nct_id>
  </id_info>
  <brief_title>Ibudilast in the Treatment of Medication Overuse Headache</brief_title>
  <official_title>Ibudilast in the Treatment of Medication Overuse Headache: A Double-blind, Randomised, Placebo-controlled Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Adelaide</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of South Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Adelaide</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if ibudilast is effective in reverting patients&#xD;
      with medication overuse headache suffering chronic daily headache back to their original&#xD;
      episodic headache pattern.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It has been established that excessive intake of medications used to treat primary headaches,&#xD;
      particularly those containing opioids, can induce a form of secondary headache, known as&#xD;
      medication overuse headache (MOH). Despite the significant clinical impact of this condition&#xD;
      the mechanisms behind MOH remain poorly understood, guidelines for treatment are lacking, and&#xD;
      relapse is common.&#xD;
&#xD;
      Recently, it has been recognised that repeated opioid exposure can facilitate pain by&#xD;
      activating glia, the immunocompetent cells of the central nervous system, resulting in&#xD;
      opioid-induced hyperalgesia (OIH).&#xD;
&#xD;
      The investigators hypothesise that MOH represents a form of OIH in this susceptible patient&#xD;
      group - repeated activation of nociceptive pathways by frequent headaches interacts with the&#xD;
      opioid induced pro-inflammatory actions of activated glia to produce chronic daily headache&#xD;
      (CDH).&#xD;
&#xD;
      This double-blind, randomised, placebo controlled pilot study will investigate the use of&#xD;
      ibudilast, a know attenuator of glial activation, in the treatment of medication overuse&#xD;
      headache.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2011</start_date>
  <completion_date type="Anticipated">August 2013</completion_date>
  <primary_completion_date type="Anticipated">June 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Headache Index</measure>
    <time_frame>2, 4, 8, 24 weeks</time_frame>
    <description>Headache Index as calculated by the summation of headache duration (hours) X headache intensity (11-point numerical rating scale), over the final two weeks of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Medication frequency</measure>
    <time_frame>2, 4, 8, 24 weeks</time_frame>
    <description>Defined as number of days acute headache medication taken over the previous month.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Headache frequency</measure>
    <time_frame>2, 4, 8, 24 weeks</time_frame>
    <description>Defined as number of days with headache over the previous month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of headache</measure>
    <time_frame>2, 4, 8, 24 weeks</time_frame>
    <description>Average duration of headache in hours over previous 2 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensity of headache</measure>
    <time_frame>2, 4, 8, 24 weeks</time_frame>
    <description>Average intensity of headache assessed by numerical rating scale over previous 2 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of probable migraine attacks</measure>
    <time_frame>2, 4, 8, 24 weeks</time_frame>
    <description>Defined as number of probable migraine attacks (using International Classification of Headache Disorders, second edition, criteria for diagnosis of migraine/migraine with aura) over previous month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Headache related impact on quality of life</measure>
    <time_frame>2, 4, 8, 24 weeks</time_frame>
    <description>As assessed via the six-item the Headache Impact Test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Allodynia symptom checklist score</measure>
    <time_frame>2, 4, 8, 24 weeks</time_frame>
    <description>Assesses presence of cutaneous allodynia during activities of daily living</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Von Frey filament test</measure>
    <time_frame>2, 4, 8, 24 weeks</time_frame>
    <description>To assess sensitivity to static mechanical cutaneous allodynia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brush allodynia test</measure>
    <time_frame>2, 4, 8, 24 weeks</time_frame>
    <description>To assess sensitivity to dynamic mechanical cutaneous allodynia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>2, 4, 8, 24 weeks</time_frame>
    <description>Response defined as ≥ 30% reduction in headache days/month or headache index from baseline. Expressed as percentage of patients who saw a ≥ 30% reduction in headache index after ibudilast treatment (at week 8) and NNT, number of patients treated to see 1 patient &quot;respond&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse rate</measure>
    <time_frame>2, 4, 8, 24 weeks</time_frame>
    <description>Expressed as the percentage of patients who were initially classed as responders (at weeks 8) who no longer meet the criteria for responders at 6 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Medication Overuse Headache</condition>
  <arm_group>
    <arm_group_label>Ibudilast</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To receive ibudilast 40mg twice daily for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>To receive placebo twice daily for 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibudilast</intervention_name>
    <description>Ibudilast 4 x 10 mg capsules, orally, twice daily for 8 weeks.</description>
    <arm_group_label>Ibudilast</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 4 capsules, orally, twice daily for 8 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Regular use, for at least 3 months, of opioid-containing analgesics on ≥ 10 days/month&#xD;
&#xD;
          -  Headache present on at least 15 days/month, for at least 2 months&#xD;
&#xD;
          -  Headache developed or markedly worsened during medication overuse&#xD;
&#xD;
          -  Primary indication for analgesics is headache disorder&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Unable to provide written informed consent&#xD;
&#xD;
          -  Age &lt; 18 years at time of screening&#xD;
&#xD;
          -  Unable to read and write in English&#xD;
&#xD;
          -  Receiving tramadol regularly&#xD;
&#xD;
          -  Taking triptans &gt; 4 days/month&#xD;
&#xD;
          -  Taking opioids for reasons other than headache (e.g. other pain conditions, cough,&#xD;
             bowel motility)&#xD;
&#xD;
          -  Severe psychiatric disorders&#xD;
&#xD;
          -  Other chronic pain conditions likely to interfere with qualitative sensory testing&#xD;
             (e.g. trigeminal neuralgia, arthritis)&#xD;
&#xD;
          -  Diabetic neuropathy&#xD;
&#xD;
          -  Recent or current active infection, determined to be clinically significant by the&#xD;
             Principal investigator&#xD;
&#xD;
          -  Known active inflammatory diseases such as rheumatoid arthritis&#xD;
&#xD;
          -  History of cerebrovascular disorder&#xD;
&#xD;
          -  Recent history of significant trauma, as determined by the Principal Investigator&#xD;
             including major surgery within the previous 2 months&#xD;
&#xD;
          -  Recent history of drug or alcohol abuse&#xD;
&#xD;
          -  Spinal cord injury&#xD;
&#xD;
          -  Any clinically significant findings on screening blood sample results&#xD;
&#xD;
          -  Current malignancy&#xD;
&#xD;
          -  Known hypersensitivity to ibudilast or excipients in Pinatos® formulation&#xD;
&#xD;
          -  Renal or hepatic impairment, defined as baseline GFR (as calculated by the&#xD;
             Cockcroft-Gault equation) of &lt; 60 mL/min or LFTs &gt; 3 times the upper limit of normal&#xD;
&#xD;
          -  For females of childbearing potential:&#xD;
&#xD;
               -  Pregnancy&#xD;
&#xD;
               -  Lack of adequate contraception (abstinence, double barrier method, intrauterine&#xD;
                  device, surgical sterilization (self or partner), hormonal contraceptive methods&#xD;
                  (oral, injected, or implanted)&#xD;
&#xD;
               -  Breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Rolan, MD FRACP</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Adelaide</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paul Rolan, MD FRACP</last_name>
    <phone>+61 8 8303 4102</phone>
    <email>paul.rolan@adelaide.edu.au</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pain and Anaesthesia Research Clinic, Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <link>
    <url>http://www.adelaide.edu.au/painresearch/</url>
    <description>Click here for more information about this study: Ibudilast in the Treatment of Medication Overuse Headache</description>
  </link>
  <reference>
    <citation>Bigal ME, Lipton RB. Excessive acute migraine medication use and migraine progression. Neurology. 2008 Nov 25;71(22):1821-8. doi: 10.1212/01.wnl.0000335946.53860.1d. Review.</citation>
    <PMID>19029522</PMID>
  </reference>
  <reference>
    <citation>Obermann M, Katsarava Z. Management of medication-overuse headache. Expert Rev Neurother. 2007 Sep;7(9):1145-55. Review.</citation>
    <PMID>17868013</PMID>
  </reference>
  <reference>
    <citation>Hutchinson MR, Bland ST, Johnson KW, Rice KC, Maier SF, Watkins LR. Opioid-induced glial activation: mechanisms of activation and implications for opioid analgesia, dependence, and reward. ScientificWorldJournal. 2007 Nov 2;7:98-111. Review.</citation>
    <PMID>17982582</PMID>
  </reference>
  <verification_date>February 2013</verification_date>
  <study_first_submitted>March 17, 2011</study_first_submitted>
  <study_first_submitted_qc>March 17, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2011</study_first_posted>
  <last_update_submitted>February 4, 2013</last_update_submitted>
  <last_update_submitted_qc>February 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 6, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Adelaide</investigator_affiliation>
    <investigator_full_name>Prof Paul Rolan</investigator_full_name>
    <investigator_title>Professor Paul Rolan</investigator_title>
  </responsible_party>
  <keyword>Medication overuse headache</keyword>
  <keyword>ibudilast</keyword>
  <keyword>glia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Headache Disorders, Secondary</mesh_term>
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibudilast</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

